Guardant Health (NASDAQ:GH) Insider Terilyn Monroe Sells 8,571 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH) insider Terilyn Monroe sold 8,571 shares of the stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $114.09, for a total value of $977,865.39. Following the transaction, the insider directly owned 20,990 shares in the company, valued at approximately $2,394,749.10. This represents a 28.99% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Guardant Health Stock Performance

GH opened at $117.28 on Friday. The business has a 50 day moving average price of $104.83 and a 200 day moving average price of $77.00. Guardant Health, Inc. has a twelve month low of $34.88 and a twelve month high of $120.74. The firm has a market cap of $14.78 billion, a P/E ratio of -36.54 and a beta of 1.58.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Wednesday, October 29th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.09. During the same period last year, the company posted ($0.88) EPS. Guardant Health’s revenue for the quarter was up 38.5% compared to the same quarter last year. As a group, analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Institutional Trading of Guardant Health

A number of hedge funds have recently modified their holdings of GH. V Square Quantitative Management LLC acquired a new stake in shares of Guardant Health during the 4th quarter worth approximately $27,000. Chesapeake Asset Management LLC bought a new position in Guardant Health in the fourth quarter worth $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Guardant Health during the fourth quarter worth $31,000. IFP Advisors Inc increased its holdings in Guardant Health by 120.1% in the 2nd quarter. IFP Advisors Inc now owns 612 shares of the company’s stock valued at $33,000 after buying an additional 334 shares during the period. Finally, Signaturefd LLC increased its holdings in Guardant Health by 50.5% in the 2nd quarter. Signaturefd LLC now owns 635 shares of the company’s stock valued at $33,000 after buying an additional 213 shares during the period. Institutional investors own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on GH shares. Mizuho set a $135.00 price target on shares of Guardant Health in a report on Friday, January 9th. Citigroup boosted their price objective on Guardant Health from $100.00 to $135.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Morgan Stanley raised their target price on Guardant Health from $105.00 to $130.00 and gave the company an “overweight” rating in a report on Monday, December 1st. UBS Group lifted their price target on Guardant Health from $80.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Finally, TD Cowen reiterated a “buy” rating on shares of Guardant Health in a report on Wednesday, January 7th. Twenty-one equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $102.81.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.